Rapid Micro Biosystems to Announce First Quarter 2022 Financial Results on May 10, 2022
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) will announce its first quarter 2022 financial results on May 10, 2022, before the market opens. A webcast conference call hosted by management will follow at 8:30 a.m. EDT, accessible via the company’s investor relations website. The company specializes in life sciences technology, focusing on automation solutions that enhance the manufacturing and quality control processes for healthcare products, including biologics and vaccines. Their Growth Direct System modernizes microbial quality control testing across pharmaceutical manufacturing globally.
- Upcoming Q1 2022 financial results announcement on May 10, 2022.
- Management will host a conference call to discuss results, enhancing transparency.
- None.
LOWELL, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2022 financial results on Tuesday, May 10, 2022, prior to the market open.
In conjunction with the release, Rapid’s management team will host a webcast conference call at 8:30 a.m. EDT on Tuesday, May 10, 2022. The live call is accessible on the Company’s website at investors.rapidmicrobio.com/ and will be archived and available for replay for one year.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.
FAQ
When will Rapid Micro Biosystems announce its Q1 2022 financial results?
What time is the conference call for Rapid Micro Biosystems Q1 2022 results?
Where can I access the webcast for the Rapid Micro Biosystems conference call?
What does Rapid Micro Biosystems do?
What is the flagship product of Rapid Micro Biosystems?
